CYP19A1 and breast cancer: Patients with this type of breast cancer are candidates for endocrine therapy, however, a number of patients will develop acquired resistance to endocrine therapy after initial treatment, and nearly 50% of advanced ERα-positive breast cancer patients do not respond to tamoxifen or aromatase inhibitors (AIs) in the first-line treatment.